"Health officials have recommended zanidatamab for those diagnosed with cholangiocarcinoma, a disease often identified at a late stage when surgical removal is no longer an option."
"Clinical trials indicate that the new treatment could almost triple the life expectancy of patients compared with existing therapies."
"Fewer than one in three people diagnosed in England survive a year post-diagnosis, and treatment options have historically been limited."
"The news has been welcomed by patients and their families, including the relatives of Huw Jones, who campaigned for the drug's widespread availability before his death earlier this year."
Zanidatamab has been approved for NHS use, providing hope for patients with cholangiocarcinoma, a cancer often diagnosed late. Clinical trials show it could nearly triple life expectancy compared to existing treatments. This is crucial as less than one in three diagnosed in England survive a year. The approval has been positively received by patients and families, particularly those like Huw Jones, who campaigned for the drug's availability before his death from the disease. His story highlights the urgent need for effective treatment options.
Read at www.independent.co.uk
Unable to calculate read time
Collection
[
|
...
]